Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria says it will fund the rollout of the twice-yearly anti-HIV jab, ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Lucy Halliday (Blue Jean) has been tapped as a lead opposite Chase Infiniti and Ann Dowd in The Handmaid’s Tale sequel The ...

Innovation in HIV care and prevention is transforming the fight, but there is more to be done in order to meet the UNAIDS targets of ending the HIV epidemic by 2030 ...

Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

A 64-year-old woman from Amston is in the hospital with life threatening injuries after a serious collision in Hebron on Monday afternoon. The accident happened at approximately 4:58 p.m. The woman ...

Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...